Globus Medical Future Growth

Future criteria checks 3/6

Globus Medical is forecast to grow earnings and revenue by 53.3% and 8.4% per annum respectively. EPS is expected to grow by 53% per annum. Return on equity is forecast to be 10.7% in 3 years.

Key information

53.3%

Earnings growth rate

53.0%

EPS growth rate

Medical Equipment earnings growth17.7%
Revenue growth rate8.4%
Future return on equity10.7%
Analyst coverage

Good

Last updated15 Aug 2024

Recent future growth updates

Recent updates

Globus Medical: A Post Acquisition Analysis

Aug 26

Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

Jun 28
Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Apr 08
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Mar 20
Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

Feb 27

Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Feb 09
Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Jan 17
Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Globus Medical: Merger Overhang Lingering

Nov 27

Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Nov 14
Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Oct 27
Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Globus Medical: Almost Having My Back

Sep 13

Globus Medical: Slightly Too Pricey Right Now

Aug 07

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

Jul 18

Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Jul 11
Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Jun 18
Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Apr 09
Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Mar 22
What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Feb 24
Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Globus Medical Q4 2022 Earnings Preview

Feb 20

Globus Medical: An Impressive Long-Term Revenue Growth Play

Jan 08

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Dec 22
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Dec 01
Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line

Nov 08

A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Oct 15
A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact

Sep 02

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Sep 02
Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Aug 11
Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective

Jun 05

Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

May 24
Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

May 06
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Earnings and Revenue Growth Forecasts

NYSE:GMED - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,845441N/AN/A10
12/31/20252,656384692N/A14
12/31/20242,48412434N/A13
6/30/20242,23741161262N/A
3/31/20241,89867152243N/A
12/31/20231,568123165243N/A
9/30/20231,226158129203N/A
6/30/20231,097204121185N/A
3/31/20231,069201117187N/A
12/31/20221,023190104178N/A
9/30/2022998155118191N/A
6/30/2022974155157235N/A
3/31/2022961142194257N/A
12/31/2021958149219276N/A
9/30/2021942187226280N/A
6/30/2021928184203256N/A
3/31/2021826122165220N/A
12/31/2020789102135199N/A
9/30/202076795108173N/A
6/30/202074789115176N/A
3/31/2020793148110175N/A
12/31/2019785155101172N/A
9/30/201977014690162N/A
6/30/201974314382158N/A
3/31/201972215093169N/A
12/31/2018713156122182N/A
9/30/2018693144126182N/A
6/30/2018676134112165N/A
3/31/2018655118N/A158N/A
12/31/2017636107N/A159N/A
9/30/2017612107N/A166N/A
6/30/2017595108N/A174N/A
3/31/2017581105N/A171N/A
12/31/2016564104N/A148N/A
9/30/2016553118N/A166N/A
6/30/2016554118N/A153N/A
3/31/2016548116N/A143N/A
12/31/2015537113N/A124N/A
9/30/2015518103N/A80N/A
6/30/201549999N/A85N/A
3/31/201548196N/A85N/A
12/31/201446792N/A79N/A
9/30/201445486N/A110N/A
6/30/201444383N/A108N/A
3/31/201443670N/A104N/A
12/31/201342769N/A93N/A
9/30/201342068N/A86N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMED's forecast earnings growth (53.3% per year) is above the savings rate (2.5%).

Earnings vs Market: GMED's earnings (53.3% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: GMED's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GMED's revenue (8.4% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: GMED's revenue (8.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GMED's Return on Equity is forecast to be low in 3 years time (10.7%).


Discover growth companies